Loading Events

All Events

Harnessing Precision Medicine to Develop Novel Therapeutic Approaches for Neurodegenerative Disease

Our upcoming Founders at Work Speaker Series features Acurex Biosciences’ Co-Founder and CSO, Bill Shrader and VP of Biology, Sean Pintchovski. Acurex, a resident company at MBC BioLabs since 2020, is dedicated to fundamentally altering the course of Parkinson’s disease with novel therapeutics guided by a new generation of precision biomarkers. This promising approach will help usher in the first era of true precision medicine in neurology.

Our Speakers

Bill Shrader, PhD
Co-Founder and CSO

Bill Shrader is the Chief Scientific Officer and Co-founder of Acurex Biosciences and has an extensive background in developing small-molecule therapeutics and biomarkers for neurodegenerative conditions.

Sean Pintchovski, PhD
VP of Biology

Sean Pintchovski, PhD has 16+ years experience in the pharmaceutical industry. During this time, he successfully led pre-clinical research teams to discover, validate, and advance several small molecules into the clinic including PTC857 (GBA-Parkinson’s disease and Amyotrophic Lateral Sclerosis) and PTC743 (Friedreich’s Ataxia). Currently, Sean is leading a talented neuroscience team to develop novel therapeutic and precision biomarker-based ‘theragnostics’ (therapeutics combined with diagnostic biomarkers) for the treatment of neurodegenerative conditions, starting with Parkinson’s disease. He received a BS with Honors from the California Institute of Technology and earned his PhD in Neuroscience from the University of California, San Francisco.


RSVP July 2, 2024
How did you hear about this event?

Feel free to share!

Go to Top